Company logo

United Therapeutics | Sustainability Performance

https://www.unither.com

Develops pharmaceuticals and medical technologies, focusing on treatments for rare diseases.

1996

United States

1,001 - 5,000 employees

Pharmaceuticals

$1B - 10B in revenue

$1B - 10B in profitability

Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.

Sustainability Ranking & Industry Benchmark

#4823
Overallⓘ
#1110
in United Statesⓘ
#103
in Pharmaceuticalsⓘ

Sustainability Maturity

ⓘ

Sustainability Intent

ⓘ

Available in
Scale package

Access

Industry Rank

110 out of 287

Overview
Environmental
Water ManagementNature and biodiversity
Social
Diversity and InclusionPay GapsExternalities
Governance
SDG Impact
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
Acer Therapeutics

United States, Health Care, Pharmaceuticals

Company logo
Intra-Cellular Therapies

United States, Health Care, Pharmaceuticals

Company logo
Parexel

United States, Health Care, Pharmaceuticals

Female employees ⓘProportion of women in the company's total workforce, expressed as a percentage.
52%2024
Leading
Externalities ⓘThe monetized estimate of environmental and social impacts caused by an organization that are not reflected in its financial accounts.
2.5M$, 2024
Leading
Market cap ⓘTotal market value of the company's outstanding shares, calculated by multiplying the share price by the number of shares outstanding.
26.1B$, 2026▼39.6% YoY
Revenue ⓘTotal revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.
2.9B$, 2024▼19.1% YoY
R&D intensity ⓘResearch and development expenditure expressed as a percentage of revenue, reflecting the company's relative investment in innovation.
16.72%2024

Intensity

Water consumption intensity (m³ /$M)
Industry Benchmark

82.2

B/M 131.1


Powered by illuminem and GIST Impact

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • United Therapeutics Corporation, US pulmonary arterial hypertension biotech, has faced sustained US DOJ scrutiny including the historic 2017 USD 210 million False Claims Act settlement over alleged inadequate co-payment assistance practices, plus the contested 2024 sustained share price volatility amid generic competition affecting institutional shareholders.
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

 Available

Sustainability employees

ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

Total sustainability employees

11+

ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.

    Available in
    Scale package

    Access